# Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis

> **NCT01703078** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 41 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Ingenol once daily for two consecutive days

## Key facts

- **NCT ID:** NCT01703078
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-03
- **Final completion:** 2013-04
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01703078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01703078, "Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01703078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*